Radiolabelled bisphosphonates and method
US6534488B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | May 8, 2002 |
| Grant date | Mar 18, 2003 |
| Priority date | — |
| Expiry date | May 8, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/409
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to 32P or 33P-labelled bisphosphonates as radiotherapeutic radiopharmaceuticals. The 32P- or 33P-labelled bisphosphonates, which are chemically identical to the unlabelled agent, are expected to target the lesion site in an identical manner, but also deliver a significant radiocytotoxic effect to the surrounding cells. This should result, given the favorable energetics of the &bgr; particle emission from the 33P nuclide, in a loss of proliferative capacity of cells associated with the tumor lesion. The relative stability and in vivo localisation of bisphosphonates makes them good candidates as 32P/33P delivery vehicles.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.